AN2 Therapeutics Inc — Cash Flow (NASDAQ:ANTX) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics Dividends

Quarterly Annual

Cash from operating activities -33.46 M-53.29 M-49.26 M-29.83 M -29.83 M Cash from investing activities -21.77 M-43.28 M54.59 M28.31 M 28.31 M Cash from financing activities 70.36 M84.99 M372 K113 K 113 K Free cash flow -33.46 M-53.29 M-49.26 M-29.83 M -29.83 M

뉴스

AN2 Therapeutics Stock Cools Off After 90% Rally - AN2 Therapeutics (NASDAQ:ANTX)

AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action? - AN2 Therapeutics (NASDAQ:ANTX)

AN2 Therapeutics raises $40M in private placement

AN2 테라퓨틱스, PV/n에페트라보롤 2상 임상시험 계획

AN2 Therapeutics plans phase 2 trial of epetraborole in PV

AN2 테라퓨틱스, Sarah Williams 회계 책임자로 임명

AN2 Therapeutics appoints Sarah Williams as principal accounting officer

FDA clears IND for epetraborole trial in mycobacterium abscessus

AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?

Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?

AN2 테라퓨틱스(ANTX) CFO Day, 8,883달러 상당 주식 매도

An2 therapeutics (ANTX): cfo Day sells $8883 in shares